Press Announcements > FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint

Press Announcements > FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint

	FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Continue reading.